Coherus Biosciences (CHRS) PT Lowered to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Coherus Biosciences (CHRS) PT Lowered to $38 at BMO Capital; 'Refiling of Neulasta Biosimilar Remains on Track for 4Q17'
August 8, 2017 9:07 AM EDTBMO Capital lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $38.00 (from $43.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst M. Ian Somaiya comments, "Coherus reported 2Q17 earnings and indicated progress towards addressing issues raised... More
